These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16163370)

  • 41. Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction.
    Chew KK; Stuckey BG; Earle CM; Dhaliwal SS; Keogh EJ
    Int J Impot Res; 1997 Dec; 9(4):225-9; discussion 229-30. PubMed ID: 9442421
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models.
    Hedlund H; Hedlund P
    Scand J Urol Nephrol Suppl; 1996; 179():129-38. PubMed ID: 8908679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prostaglandin E1 (PGE1) in diagnosis and long-term therapy of erectile dysfunction].
    Derouet H; Weirauch A; Bewermeier H
    Urologe A; 1996 Jan; 35(1):62-7. PubMed ID: 8851852
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Some aspects of the use of prostaglandin E1 in cases of erectile dysfunction].
    Fekete F
    Orv Hetil; 1997 Jun; 138(25):1631-4. PubMed ID: 9265144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intracavernosal injection therapy. Does it still have a role in erectile dysfunction?
    Chew KK
    Aust Fam Physician; 2001 Jan; 30(1):43-6. PubMed ID: 11211711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate.
    Shah PJ; Dinsmore W; Oakes RA; Hackett G
    Curr Med Res Opin; 2007 Oct; 23(10):2577-83. PubMed ID: 17875241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reasons for high drop-out rate with self-injection therapy for impotence.
    Weiss JN; Badlani GH; Ravalli R; Brettschneider N
    Int J Impot Res; 1994 Sep; 6(3):171-4. PubMed ID: 7735362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peyronie's-like plaque after penile injection of prostaglandin E1.
    Chen J; Godschalk M; Katz PG; Mulligan T
    J Urol; 1994 Sep; 152(3):961-2. PubMed ID: 8051767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of success and risk factors for attrition in the use of intracavernous injection.
    Gupta R; Kirschen J; Barrow RC; Eid JF
    J Urol; 1997 May; 157(5):1681-6. PubMed ID: 9112505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of Intracavernosal Injection of Prostaglandin E1 on Duration and Rigidity of Erection in Patients With Vasculogenic Erectile Dysfunction: Is It Dose Dependent?
    Bassiem MA; Ismail IY; Salem TA; El-Sakka AI
    Urology; 2021 Feb; 148():173-178. PubMed ID: 33017615
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections.
    Nandipati K; Raina R; Agarwal A; Zippe CD
    Int J Impot Res; 2006; 18(5):446-51. PubMed ID: 16482200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Prostaglandin E1 in the treatment of erectile insufficiency. Comparison of efficacy and tolerance based on different etiologies].
    Desvaux P; Mimoun S
    J Urol (Paris); 1994; 100(1):17-22. PubMed ID: 7916373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intracavernous injection of prostaglandin E1 is effective in patients with erectile dysfunction not responding to phosphodiseterase 5 inhibitors.
    Nagai A; Kusumi N; Tsuboi H; Ishii K; Saika T; Nasu Y; Kumon H
    Acta Med Okayama; 2005 Dec; 59(6):279-80. PubMed ID: 16418771
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction].
    Ribé N; Rajmil O; Bassas L; Jurado C; Pomerol JM
    Arch Esp Urol; 2001 May; 54(4):355-9. PubMed ID: 11455770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 56. [Prostaglandin E1--the pharmacologic prosthesis].
    de Boccard GA; Rochat CH
    Ann Urol (Paris); 1993; 27(3):152-5. PubMed ID: 8352576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [PGE1 program in erectile dysfunction: etiopathogenic and pharmacologic aspects].
    Ruiz Rubio JL; Fernández González I; Ruiz Rojas JC; Sánchez Sánchez E; Bustamante Alarma S; Berenguer Sánchez A
    Actas Urol Esp; 1996; 20(7):636-9. PubMed ID: 8975549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Penile injection in impotency.
    Gingell JC
    Hosp Med; 1998 Jul; 59(7):587. PubMed ID: 9798553
    [No Abstract]   [Full Text] [Related]  

  • 59. Intracavernosal injection therapy and surgical therapy in diabetic patients with erectile dysfunction.
    Savoca G; Silvestre G; Belgrano E
    Diabetes Nutr Metab; 2002 Feb; 15(1):53-7. PubMed ID: 11942740
    [No Abstract]   [Full Text] [Related]  

  • 60. Design and evaluation of prostaglandin E1 (PGE1) intraurethral liquid formulation employing self-microemulsifying drug delivery system (SMEDDS) for erectile dysfunction treatment.
    Lee S; Lee J; Choi YW
    Biol Pharm Bull; 2008 Apr; 31(4):668-72. PubMed ID: 18379060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.